Buy IGF-1 LR3 1mg Research Peptide Online
Insulin-like growth factor-1 Long R3 (IGF-1 LR3) represents a recombinant-DNA engineered analog of native insulin-like growth factor-1, synthesized for extended preclinical research applications examining growth factor signaling mechanisms and cellular proliferation pathways. The arginine substitution at position three significantly alters pharmacokinetic properties and binding protein interactions compared to endogenous IGF-1.
IGF-1 LR3 Peptide Classification & Recombinant Engineering
IGF-1 LR3 is an 83-amino acid recombinant peptide incorporating a strategic arginine substitution at the N-terminal position three, replacing the native alanine residue in wild-type IGF-1. This engineered modification reduces clearance rates through insulin-like growth factor binding protein (IGFBP) interactions in cell culture systems and animal models, enabling substantially extended observation windows during preclinical investigations compared to native IGF-1 pharmacokinetics.
IGF-1 LR3 Research-Documented Activation Mechanisms
Preclinical studies demonstrate IGF-1 LR3 activates the insulin-like growth factor receptor type 1 (IGF-1R), a transmembrane receptor tyrosine kinase, with receptor occupancy and activation kinetics comparable to native IGF-1. Published research documents downstream activation of phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling cascades in cell culture systems and animal models, triggering cellular proliferation and survival pathways.
IGF-1 LR3 Peer-Reviewed Research Summary
Foundational preclinical research by Clemmons et al. (1997) in Endocrinology characterized IGF-1 LR3 receptor binding affinity, kinetic parameters, and signaling activation in isolated myocyte cultures and tissue preparations. Additional research by Mauras et al. (2010) in the Journal of Clinical Endocrinology & Metabolism documented IGF-1 LR3 analog-specific pharmacokinetic profiles and metabolic clearance rates in animal models, establishing comparative data versus native IGF-1.
IGF-1 LR3 1mg Product Specifications & Technical Information
Form: Lyophilized powder (recombinant, pharmaceutical-grade) Amino Acid Composition: 83 amino acids (engineered arginine substitution at position 3) Molecular Weight: 9,197 Da Quantity: 1mg per vial Storage Conditions: -20°C (frozen); unopened stability 36 months Reconstitution: Sterile water or bacteriostatic saline per vial Purity: >99% (HPLC verified); endotoxin <1 EU/μg
IGF-1 LR3 Research Use Only Disclaimer
This product is designated exclusively for preclinical research. Not for human, veterinary, or clinical use. All protocols must follow institutional biosafety committee guidelines and applicable regulatory requirements.